{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:14:49Z","timestamp":1783516489782,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03348-7","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:24:15Z","timestamp":1783513455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of argatroban to warfarin transition process in heparin-induced thrombocytopenia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1767-477X","authenticated-orcid":false,"given":"John M.","family":"Koerber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Leeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-3770","authenticated-orcid":false,"given":"Maureen A.","family":"Smythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3348_CR1","doi-asserted-by":"publisher","unstructured":"Dhakal B, Kreuziger LB, Rein L et al (2018) Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol 5(5). https:\/\/doi.org\/10.1016\/s2352-3026(18)30046-2","DOI":"10.1016\/s2352-3026(18)30046-2"},{"key":"3348_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMcp1411910","volume":"373","author":"A Greinacher","year":"2015","unstructured":"Greinacher A (2015) Heparin-Induced thrombocytopenia. New Engl J Med 373:252\u2013261. https:\/\/doi.org\/10.1056\/NEJMcp1411910","journal-title":"New Engl J Med"},{"issue":"22","key":"3348_CR3","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2(22):3360\u20133392. https:\/\/doi.org\/10.1182\/bloodadvances.2018024489","journal-title":"Blood Adv"},{"key":"3348_CR4","unstructured":"Thrombosis Canada Clinical Guidelines - Heparin Induced Thrombocytopenia. https:\/\/thrombosiscanada.ca\/hcp\/practice\/clinical_guides?language=en-ca&guideID=HEPARININDUCEDTHROMBOCYTOPENIA, 10Sep2024. Accessed 7 March 2026"},{"key":"3348_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjh.19180","volume":"204","author":"DJ Arachchillage","year":"2024","unstructured":"Arachchillage DJ, Thachil J, Anderson JAM, Baker P, Poles A, Kitchen S, Laffan M, BSH Committee (2024) Diagnosis and management of heparin-induced thrombocytopenia: third edition. Br J Haematol 204:459\u2013475. https:\/\/doi.org\/10.1111\/bjh.19180","journal-title":"Br J Haematol"},{"key":"3348_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5694\/mja2.50213","volume":"210","author":"J Joseph","year":"2019","unstructured":"Joseph J, Rabbolini D, Enjeti A et al (2019) Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia New Zealand HIT Writing Group. Med J Aust 210:509\u2013516. https:\/\/doi.org\/10.5694\/mja2.50213","journal-title":"Med J Aust"},{"key":"3348_CR7","doi-asserted-by":"publisher","unstructured":"Linkins LA, Warkentin TE, Koster A et al (2012) Treatment and prevention of heparin-induced thrombocytopenia: 2012 guidelines. Chest 141(2): e27S-e44S. https:\/\/doi.org\/10.1378\/chest.11-2872","DOI":"10.1378\/chest.11-2872"},{"issue":"4","key":"3348_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1309\/D79K-4YG7-8NTN-YY38","volume":"121","author":"RC Gosselin","year":"2004","unstructured":"Gosselin RC, Dager WE, King JH et al (2004) Effect of direct thrombin inhibitors, bivalirudin, lepirudin and argatroban on prothrombin time and INR values. Am J Clin Pathol 121(4):593\u2013599. https:\/\/doi.org\/10.1309\/D79K-4YG7-8NTN-YY38","journal-title":"Am J Clin Pathol"},{"key":"3348_CR9","doi-asserted-by":"publisher","unstructured":"Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK (2001) Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin [published correction appears in Thromb Haemost 2001;86(2):727]. Thromb Haemost 85(3):435\u2013440. https:\/\/doi.org\/10.1055\/s-0037-1615601","DOI":"10.1055\/s-0037-1615601"},{"key":"3348_CR10","unstructured":"Argatroban Package insert (2023) Fresenius Kabi USA LLC"},{"issue":"3","key":"3348_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11239-005-1849-9","volume":"19","author":"JR Bartholomew","year":"2005","unstructured":"Bartholomew JR, Hursting MJ (2005) Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 19(3):183\u2013188. https:\/\/doi.org\/10.1007\/s11239-005-1849-9","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"3348_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/107602960501100306","volume":"11","author":"MJ Hursting","year":"2005","unstructured":"Hursting MJ, Lewis BE, Macfarlane DE (2005) Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 11(3):279\u2013287. https:\/\/doi.org\/10.1177\/107602960501100306","journal-title":"Clin Appl Thromb Hemost"},{"key":"3348_CR13","unstructured":"Argatroban product monograph- Canadian https:\/\/pdf.hres.ca\/dpd_pm\/00076134.PDF. Accessed 7 March 2026"},{"key":"3348_CR14","unstructured":"Argatroban product documentation, Healthcare UK https:\/\/accord-healthcare-products.co.uk\/products\/a\/argatroban-solution. Accessed 7 March 2026"},{"key":"3348_CR15","unstructured":"Pishko AM, Linkins LA, Warkentin TE, Cuker A (2018) Diagnosis and management of heparin-induced thrombocytopenia: pocket guide. American Society of Hematology; December 2018"},{"issue":"4","key":"3348_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3348_CR17","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3348_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee of Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202\u2013204. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03678.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3348_CR19","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/jth.14587","volume":"17","author":"AM Pishko","year":"2019","unstructured":"Pishko AM, Lefler DS, Gimotty P et al (2019) The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia (HIT). J Thromb Haemost 17(11):1956\u20131965. https:\/\/doi.org\/10.1111\/jth.14587","journal-title":"J Thromb Haemost"},{"key":"3348_CR20","doi-asserted-by":"publisher","unstructured":"Douketis JD, Spyropoulos AC, Kaatz S et al (2015) Perioperative bridging anticoagulation in patients with atrial fibrillation. New Engl M Med 2015;373:823\u2013833. https:\/\/doi.org\/10.1056\/NEJMoa1501035","DOI":"10.1056\/NEJMoa1501035"},{"issue":"9","key":"3348_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","volume":"127","author":"TE Warkentin","year":"1997","unstructured":"Warkentin TE (1997) The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Int Med 127(9):804. https:\/\/doi.org\/10.7326\/0003-4819-127-9-199711010-00005","journal-title":"Ann Int Med"},{"issue":"4","key":"3348_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.accreview.2004.03.080","volume":"13","author":"AF Srinivasan","year":"2004","unstructured":"Srinivasan AF, Rice L, Bartholomew JR (2004) Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. ACC Curr J Rev 13(4):12\u201313. https:\/\/doi.org\/10.1016\/j.accreview.2004.03.080","journal-title":"ACC Curr J Rev"},{"issue":"1","key":"3348_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajh.10181","volume":"71","author":"MA Smythe","year":"2002","unstructured":"Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC (2002) Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 71(1):50\u201352. https:\/\/doi.org\/10.1002\/ajh.10181","journal-title":"Am J Hematol"},{"issue":"3 Suppl","key":"3348_CR24","doi-asserted-by":"publisher","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","volume":"126","author":"TE Warkentin","year":"2004","unstructured":"Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest 2005;127(1):416]. Chest 126(3 Suppl):311S\u2013337S. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.311S","journal-title":"Chest"},{"key":"3348_CR25","doi-asserted-by":"publisher","unstructured":"Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [published correction appears in Chest. 2011;139(5):1261. Dosage error in article text]. Chest 133(6 Suppl):340S-380S. https:\/\/doi.org\/10.1378\/chest.08-0677","DOI":"10.1378\/chest.08-0677"},{"key":"3348_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.thromres.2016.05.023","volume":"144","author":"LD Chen","year":"2016","unstructured":"Chen LD, Roberts AJ, Dager WE (2016) Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia. Thromb Res 144:229\u2013233. https:\/\/doi.org\/10.1016\/j.thromres.2016.05.023","journal-title":"Thromb Res"},{"key":"3348_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0033-1363475","volume":"40","author":"JI Tange","year":"2014","unstructured":"Tange JI, Grill D, Koch CD et al (2014) Local verification and assignment of mean normal prothrombin time and International Sensitivity Index values across various instruments: recent experience and outcome from North America. Semin Thromb Hemost 40:115\u2013120. https:\/\/doi.org\/10.1055\/s-0033-1363475","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"3348_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bjh.18120","volume":"197","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Barelli S, Gleich T et al (2022) Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia. Br J Haematol 197(6):766\u2013790. https:\/\/doi.org\/10.1111\/bjh.18120","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03348-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:24:18Z","timestamp":1783513458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03348-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":28,"alternative-id":["3348"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03348-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was granted an exemption by the health system\u2019s Institutional Review Board (IRB).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}